52 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 ROUNDTABLE and personalised medicine. We’re seeing increased complexity in the supply chain and greater scrutiny on sustainability and regulatory compliance. One key trend we’re monitoring is how strategic partners are being expected to do more throughout the lifecycle of the drug. That’s pushing us to enhance not only our service offering but also how we position and communicate our value to clients in a highly competitive space. Are there particular therapeutic areas or modalities where you see the most growth potential right now? PV. Beyond the therapeutic advances themselves, we see enormous growth potential in drug packaging and delivery solutions. As individualised medicine continues to expand, the demand for customised packaging is rising rapidly – not just in terms of compliance and safety, but also in patient usability. A major focus at Tjoapack is on injectables: traditionally, we have supported vials, but the market demand for more complex packs has clearly grown. Tjoapack now also offers automated packaging of prefilled syringes and more recently labelling and packaging of autoinjector pens. These formats are critical for patient-centric care, as they enable self-administration and improve adherence. For us, the real growth lies in providing end-to-end solutions that adapt to evolving modalities while keeping scalability and regulatory requirements front of mind. ML. From our perspective, the most dynamic growth in nucleic acid therapeutics is in siRNA and mRNA-based medicines. Cardiometabolic siRNA programs targeting genes such as PCSK9, ApoC3, AGT and Lp(a) are advancing rapidly toward commercial approval. These therapies could serve tens of millions of patients worldwide, requiring unprecedented production capacity for RNA therapeutics. Equally exciting are innovations in targeted delivery and advanced modalities, including personalised cancer vaccines, in vivo CAR-T therapies and CRISPR-based gene editing drugs that require long guide RNAs. Clinical adoption of technologies that enhance the potency and durability of the mRNA payloads of these drugs is accelerating, creating new opportunities for transformative treatments. Hongene is uniquely positioned to support these innovations. With vertically integrated capabilities spanning raw material production through GMP oligonucleotide and mRNA CDMO services, and with chemoenzymatic ligation technology for high-purity siRNA and sgRNA manufacturing, we provide end-to-end scalable solutions that minimise risk and accelerate timelines. By combining next-generation technologies with world-leading vertically integrated manufacturing capacity, Hongene ensures RNA therapeutics are not only scientifically viable, but also manufacturable at the scale needed for global patient access and impact. BC. The strongest growth in the pharmaceutical market is being driven by therapeutic advances in biologics, coupled with rapid progress in bioprocessing and analytical sciences. Discoveries in drug characterisation – such as highresolution mass spectrometry, next-generation chromatography and novel potency bioassays – are enabling developers to better define molecular attributes earlier in the pipeline. At the same time, new types of bioreactors optimised for high-productivity cell lines are making large-scale biologics manufacturing more efficient and costeffective. These innovations directly support the expansion of advanced biologic therapies, particularly orphan drugs for rare diseases, which continue to benefit from regulatory incentives and high unmet medical needs. Monoclonal antibodies remain the leading biologics segment and will continue to be central to innovation in the coming decade. They are not only the backbone of many oncology and immunology pipelines, but are also being investigated in newer areas such as neurodegenerative and metabolic diseases. The ability of mAbs to combine high specificity with predictable safety and efficacy makes them a modality that will retain strategic importance for both innovators and biosimilar developers. Beyond traditional mAbs, novel modalities are generating significant momentum. ADCs represent one of the most exciting areas, with the market expected to grow at an estimated 20% compound annual growth rate. Their targeted approach to delivering cytotoxic payloads directly to cancer cells has shown encouraging results in breast, lung and hematological malignancies, and more indications are under investigation. This precision reduces systemic toxicity, making ADCs a highly attractive class. Multi-specific antibodies are another promising modality, designed to bind multiple targets or bridge distinct cells simultaneously. This creates novel therapeutic mechanisms, particularly in oncology and immune-mediated diseases, where
RkJQdWJsaXNoZXIy MjY2OTA4MA==